Pharma Co wins appeal for full commission payment claim. Revenue's appeal dismissed, evidence and consistency key.

The tribunal allowed the pharmaceutical company's appeal, directing the AO to allow the full commission payment claim of Rs. 67,77,001/-. The Revenue's appeal to restore the entire disallowance was dismissed, emphasizing the need for concrete evidence and consistency with previous assessments.

---

---

Issues Involved:
1. Disallowance of commission payments amounting to Rs. 67,77,001/-.
2. Verification and restriction of commission payment rate to 3%.

Detailed Analysis:

1. Disallowance of Commission Payments:
The case revolves around the disallowance of commission payments amounting to Rs. 67,77,001/- made by the assessee, a pharmaceutical company, to 13 parties. The Assessing Officer (AO) disallowed these payments despite the assessee providing all relevant details, including confirmations, PAN particulars, TDS deductions, and agreements. The AO's primary contention was the lack of proof of services rendered by the payees. The CIT(A) partially accepted the assessee's appeal, noting that the AO did not prove the expenditure as non-genuine and failed to gather positive evidence by examining the commission agents. The CIT(A) acknowledged the genuineness of the expenditure but directed the AO to verify the rate of commission and restrict it to 3%.

2. Verification and Restriction of Commission Payment Rate:
The CIT(A) observed that the rate of commission payments ranged from 2% to 24%, which seemed excessively high. The CIT(A) noted that the agreements did not specify the rate of commission and that the assessee failed to produce evidence such as sales details or communications from the commission agents. Consequently, the CIT(A) directed the AO to allow the commission payments after verifying and restricting the rate to 3%. However, the tribunal found no cogent reason for the AO or CIT(A) to adopt a different approach from previous assessments, where such commission expenses were accepted as a routine practice in the pharmaceutical business. The tribunal noted that the assessee had deducted TDS at prescribed rates and provided all necessary confirmations. The tribunal concluded that the CIT(A) erred in restricting the commission payments to 3% without any comparative market rate analysis and directed the AO to allow the entire claim of Rs. 67,77,001/-.

Conclusion:
The tribunal allowed the assessee's appeal, directing the AO to allow the full commission payment claim of Rs. 67,77,001/-. The Revenue's appeal to restore the entire disallowance was dismissed. The judgment emphasized the importance of providing concrete evidence and maintaining consistency with previous assessments.

---